Compare Cincinnati Financial Corporation (CINF) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cincinnati Financial Corporation vs Novo Nordisk A/S — how do they compare? Cincinnati Financial Corporation trades at $173.08 (market cap $26.58B), while Novo Nordisk A/S trades at $46.11 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 7.8× Cincinnati Financial Corporation's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| CINF | NVO | |
|---|---|---|
Market Cap | $26.58B | $207.85B |
Sector | Financials | Health |
52-Week High | $192.03 | $63.98 |
52-Week Low | $149.79 | $35.29 |
Enterprise Value | $25.71B | $222.55B |
Dividend Yield | 2.17% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cincinnati Financial (CINF) trades at $173.86, down 1.7% on the day, with a bearish technical signal and key support at $172. The company reported mixed Q2 2026 earnings, missing EPS estimates but showing revenue growth. Strong fundamentals include a low P/E of 8.18, robust ROE of 21.48%, and a consistent dividend history, with a recent H1-26 dividend of $0.94 declared.
The outlook is cautiously optimistic, supported by a consensus price target of $195 and a 'Moderate Buy' analyst rating. Risks include catastrophe losses impacting underwriting and competitive pressures in commercial lines. Positive cash flow trends and rising investment income provide a solid foundation for long-term growth.
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cincinnati Financial Corporation
Cincinnati Financial Corp is a property and casualty insurance company that generates income through written premiums. A select group of independent agencies actively markets the company's business, home, and automotive insurance within their communities. These agents offer the company's personal lines as well as its standard market, excess, and surplus commercial line policies in many regions in the United States. Cincinnati Financial also offers leasing and financing services. The vast majority of the company's revenue is generated through commercial lines, followed by personal lines.
Read more on CINF →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
